Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

Online
ISSN
1437-4331
See all formats and pricing
Volume 48, Issue 1 (Jan 2010)

Issues

Plasma nitrite/nitrate concentrations in patients with schizophrenia

Vladimir V. Djordjević
  • Clinic for Mental Health Protection, Clinical Centre Niš, Niš, Serbia
/ Ivana Stojanović
  • Institute of Biochemistry, Faculty of Medicine, Niš, Serbia
/ Dragana Stanković-Ferlež
  • Centre for Medical Biochemistry, Clinical Centre Niš, Niš, Serbia
/ Tatjana Ristić
  • Centre for Medical Biochemistry, Clinical Centre Niš, Niš, Serbia
/ Dušan Lazarević
  • Clinic for Psychiatry, Clinical Centre Niš, Niš, Serbia
/ Vladan Ćosić
  • Centre for Medical Biochemistry, Clinical Centre Niš, Niš, Serbia
/ Vidosava B. Djordjević
  • Institute of Biochemistry, Faculty of Medicine, Niš, Serbia

Abstract

Background: Nitric oxide (NO) is known to be a signaling molecule with many physiogical functions including apoptotic process regulation. Since apoptosis may contribute to the pathophysiology of schizophrenia, this study was undertaken to determine the plasma concentrations of NO in schizophrenics.

Methods: Nitrite/nitrate (NO2/NO3) concentrations were measured in plasma from 40 patients with schizophrenia, and 36 age- and gender-matched healthy persons using a colorimetric test.

Results: Plasma NO2/NO3 concentrations were significantly higher in patients with schizophrenia (102.8±34.7 μmol/L, p<0.0001) than in controls (69.2±13.2 μmol/L). Also, mean NO2/NO3 values in female patients and controls were significantly higher (118.2±44.7 μmol/L, p<0.001; 74.8±16.1 μmol/L, p<0.05, respectively) compared to males (94.7±25.3 μmol/L, 67.6±10.8 μmol/L). Significant correlation was seen between plasma NO2/NO3 concentrations and heredity, number of episodes and peripheral blood mononuclear cell (PBMC) caspase-3 activity, which was significantly higher in patients than in controls (p<0.05). There was no significant difference in NO2/NO3 concentrations between patients with different Positive and Negative Syndrome Scale (PANSS) scores or between patients treated with haloperidol (97.2±31.2 μmol/L) and those treated with other atypical antipsychotic drugs (109.8±33.7 μmol/L). Both parameters showed no significant differences between smokers and non-smokers.

Conclusions: This study showed that plasma NO2/NO3 concentrations were significantly increased in patients with schizophrenia, being significantly higher in female than male patients, and showing a significant correlation with heredity, number of episodes and PBMC caspase-3 activity. These results suggest that NO could be considered an inducer or regulator of apoptosis in patients with schizophrenia.

Clin Chem Lab Med 2010;48:89–94.

Keywords: caspase-3 activity; nitrite/nitrate; schizophrenia

About the article

Corresponding author: Prof. Dr. Vidosava B. Djordjević, PhD, Institute of Biochemistry, Faculty of Medicine, Bul. dr Zorana Djindjića 81, 18000 Niš, Serbia


Received: 2009-05-09

Accepted: 2009-09-10

Published in Print: 2010-01-01


Citation Information: Clinical Chemistry and Laboratory Medicine, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2010.014. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Atefeh Zeinoddini, Morvarid Ahadi, Mehdi Farokhnia, Farzin Rezaei, Mina Tabrizi, and Shahin Akhondzadeh
Journal of Psychiatric Research, 2014, Volume 59, Page 125
[2]
Logan T. Knox, Yu Jing, Nicola D. Collie, Hu Zhang, and Ping Liu
Neuropharmacology, 2014, Volume 81, Page 195
[3]
Yu Jing, Hu Zhang, Amy R. Wolff, David K. Bilkey, and Ping Liu
Schizophrenia Research, 2013, Volume 148, Number 1-3, Page 151
[4]
João Paulo Maia-de-Oliveira, Clarissa Trzesniak, Irismar R. Oliveira, Matthew J. Kempton, Tatiana M. N. de Rezende, Sandro Iego, Glen B. Baker, Serdar M. Dursun, João Paulo Machado-de-Sousa, and Jaime E.C. Hallak
Revista Brasileira de Psiquiatria, 2012, Volume 34, Page 149
[5]
Dušan Lazarević, Vladimir Đorđević, Vladan Ćosić, Predrag Vlahović, Suzana Tošić-Golubović, Tatjana Ristić, and Vidosava Đorđević
Journal of Medical Biochemistry, 2011, Volume 30, Number 1
[6]
José Vicente Negrete-Díaz, Eduardo Baltazar-Gaytán, María Elena Bringas, Rubén Antonio Vazquez-Roque, Stephanie Newton, Patricia Aguilar-alonso, Bertha Alicia León-Chávez, and Gonzalo Flores
Synapse, 2010, Volume 64, Number 12, Page 941

Comments (0)

Please log in or register to comment.
Log in